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Abstrak 
Latar belakang: Hasil uji klinik terdahulu terhadap artemisinin-naftokuin (ANT) dosis sekali minum pada 
pengobatan pasien dewasa dengan malaria tanpa komplikasi menunjukkan aman, dapat ditoleransi, dan 
sangat efektif. Data tambahan dibutuhkan untuk verifi kasi keamanan dan efi kasi dari kelompok umur 
lainnya sebelum obat baru ini dapat digunakan secara luas di Puskesmas di Indonesia.
Metode: Pada penelitian ini, kami menggunakan modifi kasi pedoman uji klinis WHO 2009. Studi kuasi-
eksperimental ini membandingkan dua paralel grup, subjek dengan ANT di 5 puskesmas rawat inap, dan subjek 
dengan obat kontrol dihidroartemisinin-piperakuin (DHP) minum obatnya di 5 puskesmas rawat jalan. 
Hasil: Dari total 182 subjek yang direkrut, 168 kasus malaria yang dianalisis dalam uji klinik ini. Mereka 
adalah 71 kasus dalam ANT grup dan 97 kasus dalam DHP grup. Karakteristik subjek yang mendapat 
ANT dan DHP saat rekrutmen adalah Sama kecuali proporsi subjek dengan suhu aksila ≥37.50C, dan 
proporsi subjek dengan anemia (Hb <11 g/dl) di ANT grup lebih tinggi dibanding DHP grup (61.8% vs 
23.8%, and 83.1% vs 48.5%). Subjek ANT grup juga lebih rendah proporsi parasite asexualnya pada hari 
ke-3 dibanding DHP grup (1.4% vs 10.3%). Efi kasi terapetik ANT dan DHP adalah 95.1 % (95% CI: 88.8-
99.1) dan 91.9%  (95% CI:84.3-96.0) pada hari 42. Kedua obat memiliki kejadian sampingan ringan.
Kesimpulan: Penggunaan ANT adalah aman dan memiliki efi kasi yang sama dengan DHP untuk 
pengobatan pasien dewasa dan anak dengan malaria tanpa komplikasi di Puskesmas. (Health Science 
Indones 2014;2:101-5)
Kata kunci: semua umur, malaria, artemisinin-naftokuin, dihidroartemisinin-piperakuin, puskesmas.
Abstract
Background: Our previous study of single dose artemisinin-naphthoquine (ANT) in adult majority male 
patients showed it as a safe, tolerable, and very effective treatment for uncomplicated malaria. More data 
is required to verify safety and effi cacy from other age groups before this new drug could be widely used 
in Primary Health Care (PHC)s in Indonesia.
Methods: For this  study, we modifi ed the 2009 WHO guidelines for clinical trials. This quasi-experimental study 
compared two parallel groups, subjects given ANT at 5 PHCs with inpatient facilities, and subjects given the 
control drug dihydroartemisinin-piperaquine (DHP) administered to subjects at 5 PHCs without inpatient facilities.  
Results: Of a total 182 recruited subjects, 168 malaria cases could be analyzed. There were 71 cases in 
the ANT group and 97 cases in the DHP group. The characteristics of subjects receiving ANT and DHP  at 
baseline were similar except the proportion of axillary temperature  ≥37.50C, and proportion of anaemic 
subjects (Hb <11 g/dl) in the ANT group were higher than DHP group (61.8% vs 23.8%, and 83.1% vs 
48.5%). Subjects in ANT group also had a lower proportion of asexual parasitemia on day-3 than DHP 
group (1.4% vs 10.3%). The therapeutic effi cacy of ANT and DHP, were 95.1% [95% confi dence interval 
(CI) = 88.8-99.1] and 91.9%  (95% CI = 84.3-96.0) by day 42. Both drugs had mild adverse events.
Conclusion: The use of ANT is safe and has similar effi cacy to DHP for treatment of adults and children 
patient with uncomplicated malaria at Primary Health Care. (Health Science Indones 2014;2:101-5)
Key words: malaria, artemisinin-naphthoquine, dihydroartemisinin-piperaquine, primary health care.
Vol. 5, No. 2, December 2014 Uncomplicated malaria treatment at Primary Health Care 101
Using Artemisinin-based Combination Therapy 
(ACT) is one of four efforts to accelerate the 
elimination of malaria in Indonesia.1 Currently the 
ACT preparation that is free  for widespread use in 
Indonesia is dihydroartemisinin-piperaquine (DHP). 
Dihydroartemisinin-piperaquine is a fi xed dose of 
combination 40 mg dihydroartemisinin and 320 mg 
piperaquine phosphat, once daily for three days. This 
drug is a combination of an active metabolite form 
of artemisinin and piperaquine. Artemisinin  quickly 
eliminates parasites in early day of onset while 
piperaquine with its  long half-life between 19 and 28 
days eliminates the residual parasites. Recently drug 
(ACT) monitoring conducted by National Institute 
of Health Research and Development (NIHRD), 
Indonesia shows DHP is safe and effective with the 
cure rates of higher than 95% for the treatment of 
uncomplicated malaria.2-4 Our previous study with 
ANT conducted in adult (majority male) patients 
showed ANT to be very effective (>95%), safe and 
tolerable for treatment of uncomplicated malaria.5 
The primary objective of this trial was to compare 
the safety and effi cacy of ANT with DHP, moreover 
there are other objectives as follow: to compare the 
proportion of fever clearance and asexual parasite 
clearance on day-3 follow up of ANT with DHP for 
the treatment of uncomplicated malaria in adults and 
children at Primary Health Care.
ME THODS
Study design
This is a quasi-experimental trial, two parallel groups 
and multi-canters held from August to November 
2012, at 10 PHCs in 5 provinces of Indonesia. The 
highest malaria endemic district was selected from 
each province, and from each district two PHCs, 
one with and one without in patient facility were 
chosen as the trial locations. Considering the safety 
of a new study drug and the fi rst drug trial conducted 
at the PHC level, 5 PHCs with inpatient facilities 
were assigned as study (ANT) group locations, and 
another 5 PHCs without inpatient facilities were 
assigned as comparators. 
Study subjects and procedures
Subjects with uncomplicated malaria were enrolled 
from outpatient clinics at PHCs as well as from 
referred symptomatic malaria subjects from active 
case fi nding (mass blood survey) in the district.  The 
inclusion criteria are as follows: having  positive any-
malaria by microscopy, age more than six months 
with minimum body weight 7 kgs, and able to orally 
consume medicine. The exclusion criteria are subjects 
with severe or complicated malaria, suffering from 
severe diseases, under nourished, having severe 
anemia (Hb<8 g/dl), having fever caused by other 
causes instead of malaria, having ACT allergic history, 
or pregnant or breast feeding women. 
The study was conducted based on the 2009 World 
Health Organization (WHO) guidance.6  Subjects 
are followed-up on day 3, 7, 14, 21, 28, 35, 42 and 
at any time the subject feels ill.  C on sidering ANT 
is administered only on day 0, and to adjust to the 
conditions and diffi culties of subjects using health 
services in the remote areas, we  modifi ed the 
schedule of follow-up of the subjects to  day 3, 14, 
28 and 42 (every two weeks).
A standard case Record Form (CRF) was completed to 
record demographic information (age, sex and body 
weight)  details of symptoms (including symptoms 
duration). Clinical  fi ndings were documented  and 
the axillary temperature were measured with a digital 
thermometer. Thick and thin smears were examined 
at day-0, 3, 14, 28, and 42, and to evaluate healing 
improvement hemoglobin was measured on day-0, 
14, 28, and 42. Blood spot for PCR examination 
was collected on day 0 and on day of failure, to 
distinguish between recrudescent and new infection 
of P.falciparum infection. Subjects were allowed to 
go home after the doctor explained the results of the 
microscopic examination on each visit. 
Microscopic examination was done by a trained 
microscopist in each PHC, and later was validated 
by NIHRD microscopists in Jakarta. Hemoglobin 
examination was performed using the Sahli method 
by laboratory staff of PHC. Blood spot sample for 
PCR examination was collected by trained laboratory 
staff in PHC, while the  examination was conducted 
in the NIHRD laboratory. 
Study drugs
Eligible subjects in  the study group were given 
ANT (Arco®, no. batch 12DB) based on artemisinin 
dosage of 14 - 30 mg/kg body weight and 
naphthoquine 5.5 - 12 mg/kg body weight, single 
dose under 1 hour supervision. In the comparator 
group, eligible subjects received DHP (Darplex®, 
no. batch 11HB) based on dihydroartemisinin 
dosage of 2 - 4 mg/kg body weight and piperaquine 
16 - 32 mg/kg body weight, single dose daily for 
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three days. The administration of fi rst dose of DHP 
was supervised, and the second and third doses were 
given in a package and administered at home after 
24 hours and at 48 hours. If  subject vomited within 
60 minutes after taking the drugs, the full dose of 
ANT or DHP was reintroduced. Subjects who 
vomited  for the second time were excluded from 
the study. These subjects were counted as protocol 
violations and were treated with parenteral treatment 
according to standard malaria treatment protocol 
at PHC. Following the treatment policy for radical 
treatment, primaquine was given together with the 
ACT without G-6PD test. The dosage of primaquine 
for subjects infected with P.falciparum was 0.75 mg 
of base/kg of body weight, single dose; and 0.5 mg 
of base/kg of body weight for 14 days for P.vivax 
infection or mixed P.falciparum-P.vivax infection. 
The administration of primaquine was  done by the 
subjects  in their home.
Subjects with recurrent asexual parasitemia on 
follow-up, between day 7 and day 42,  were retreated 
with alternative antimalarial drugs according to 
standard malaria control treatment guideline. 
Outcome evaluation
The primary effi cacy endpoints in our study were 
proportion of treatment success on day 14 , 28 and 
42 . Our secondary effi cacy endpoints were  the 
proportion of fever clearance and asexual parasitemia 
clearance on day 0 and day 3.6 Therapeutic response 
was determined using clinical and parasitological 
criteria. Estimates of effi cacy were derived from all 
patients who did not violate any of the inclusion or 
exclusion criteria. Per Protocol (PP) evaluation was 
performed to all subjects on ANT and on DHP who 
completed the study according to protocol. We did 
not check that all subjects on DHP took all their 
doses at their home.  Whereas modifi ed intention 
to treat (mITT) analysis was performed on the PP 
population and on subjects who were lost to follow-
up or who withdrew consent. 
The safety were reported as the proportion of adverse 
events during 42 days of follow up. Adverse events 
refers to events that appeared after the intervention 
during follow-up, regardless its relation with the 
treatment. 
Statistical analysis
Central researchers visited study sites to monitor 
the completeness of data monthly. Completed and 
cleaned CRFs were brought to NIHRD for data entry 
using Epi Data software version 3.1 and analyzed with 
SPSS software version 17. The student’s t-test was 
used for comparison of the two groups. Difference in 
proportions were examined using Fisher’s exact test.
Ethics
This trial was approved in writing by the Ethics 
Committee of National Institute of Health Research 
and Development, Ministry of Health, and the Bureau 
of Food and Drug Control, Republic of Indonesia.
RESULTS
A total of 182 subjects with uncomplicated malaria 
were recruited in this trial at 10 PHCs during 
September-November 2012.  We could not recruited 
as many subjects as the planned sample size because 
the incidence of malaria has decreased since the 
planning stage. Thirteen subjects were excluded due 
to microscopic errors and one false positives). Of the 
168 remaining cases, there were 71 subjects in the 
ANT group (40 subjects had P.falciparum infection, 
24 subjects with P.vivax and 7 subjects with mixed 
infection of P.falciparum and P.vivax) and 97 subjects 
in the DHP group (63 subjects with P.falciparum, 29 
subjects with P.vivax and fi ve subjects with mixed 
infection of P.falciparum and P.vivax) (Figure 1).
Of the 71 recruited subjects in ANT group, 10 cases 
did not complete the study. Six subjects withdrew 
their consent (1 P.falciparum withdrawn on day 3, 2 
P.vivax withdrawn on days 0 and 3 mixed infection 
of P.falciparum and P.vivax withdrawn on days 
0 and 3) and 4 subjects were lost to follow up (2 
P.falciparum on day 28, and 2 P.vivax on days 3 and 
28). There were also 10 cases in the DHP group that 
did not complete the trial. One subject  withdrew 
consent (P.falciparum withdrawn on day 0), 2 took 
other antimalarial drugs (1 P.falciparum on day 6 
and 1 P.vivax on day 28), and 7 were lost to follow 
up (3 P.falciparum on days 0 and 3, and 3 P.vivax on 
days 0 and 28, 1 mixed infection of P.falciparum and 
P.vivax on day 0).
Signifi cance difference between two groups were 
found in terms of age, baseline fever, history of fever 
and their anemic state. The patients in ANT group 
were slightly older, more feverish, had less history of 
fever and more anemic. Although the difference was 
not signifi cant, the ANT group had younger patients, 
higher mean weight, narrower range of parasitemia 
and more gamectocytes carrier (See table 1). 
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Figure1. Flow diagram of subject recruitment in Artemisinin Naphthoquine (ANT) 
and Dihydroartemisinin Piperaquine (DHP) groups
Table 1. Several characteristics of the subjects at baseline (day 0) and on day 3 of follow-up in Artemisinin Naphthoquine and 
Dihydroartemisinin Piperaquine groups 
Characteristics
Type of treatment
   p
Artemisinin Naphthoquine Dihydroartemisinin Piperaquine
Age (years), median (range) 14.0 (1 – 57.0) 13.0 (1 – 73.0) 0.04
Type of parasites, n (%)
P. falciparum 40 (56.3%) 63 (64.9%) 0.94
P. vivax 24 (33.8%) 29 (29.9%) 0.14
  Mixed P. falciparum- P. vivax   7 (9.9%)   5 (5.2%) 0.75
Male subjects, n (%) 39 (54.9%) 52 (53.6%) 0.90
Weight, mean (range) kg 38 (8 - 75) 29 (7 - 84) 0.41
Anemia, n (%) 59 (83.1%) 48 (48.5%) 0.00
History of fever,n (%) 47 (66.2%) 85 (81.0%) 0.00
Fever (> 37,50C),  n (%)
Day 0 47 (61.8%) 25 (23.8%) 0.00
Day 3 1 (1.4%)   2 (2.1%) 0.79
Asexual parasitemia 
      Baseline interquartile range (Q1-Q3), parasitaemia per uL 364.1–5870.7 197.6–9237.9
Day 0, n (%) 71 (100%) 97 (100%) 1.00
Day 3, n (%)   1 (1.4%) 10 (10.3%) 0.05
Gametocytaemia carrier, n (%) 20 (26.3%) 21 (20.0%) 0.43
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At day 3 of follow up, ANT group showed a 
better improvement than the DHP group. It had a 
lower proportion of patient with fever and asexual 
parasitemia (1.4% vs.2.1 % for fever and 1.4% vs. 
10.3 % for asexual parasitemia). 
In table 2, we showed that either in mITT or PP 
population, the ANT and DHP showed similar rate of 
effi cacy in day 14, 28 and 42. The rate of uncorrected 
and corrected effi cacy were reached more than 80 
% in both groups as soon as day 14. A total of 10 
subjects had recurrent parasitemia during follow-up 
(two subjects in the ANT group and eight subjects 
in the DHP group). The two recurrences in the 
ANT group were both attributable to P. falciparum; 
and the eight recurrences in the DHP group  were 
attributable to: six P. falciparum, one P. vivax and 
one mixed infection P. falciparum and P. vivax. 
In general, subjects in ANT group experienced less 
adverse events compared to subjects in DHP group. 
In ANT group, the most common adverse events 
were anorexia (5.6%), while in DHP group, it was 
coughing (15.5%). Abdominal pain and diarrhea 
occurred more often in DHP group compared to 
ANT group (7.2% vs. 1.4%). 
DISCUSSION
In this study, ANT combination is well tolerated for 
the treatment of patients with uncomplicated malaria 
in PHC facilities. Although we failed to complete the 
patients recruitment, our study fi nd similar cure rates 
at day 42 after treatment with ANT (96%) and DHP 
(92 %) with previous studies. Additionally, in terms 
of safety, we found that ANT has a similar safety 
profi le as DHP. 2-4,  7-10  
In 2003, researchers in China developed a new 
generation of ACT, which is ‘single dose’ artemisinin-
naphtoquine (ANT). This is a combination of a fi xed-
dose, containing 125 mg of artemisinin and 50 mg of 
naphthoquine base (78.3 mg of naphthoquine phosphate). 
Artemisinin has a rapid onset of schizontocidal action, 
while the naphthoquine phosphate in the combination 
has a long half life (11.5 days).11
In our study, the effi cacy rate of ANT had reached 
above 80 % for both treatment groups as soon as 
day 14 and had stay constant until day 42. Although 
DHP seems to perform better in mITT analysis 
while ANT showed higher percentage of effi cacy in 
PP analysis, their differences were not signifi cant. 
Thus, we believe both treatments performed 
similarly. This effi cacy profi le was consistent with 
our previous multicentre study in adult patients with 
uncomplicated malaria.5  
In terms of safety, eventhough we use d a higher dose 
of artemisinin (15 -30 mg/kg) compared to WHO 
recommendation (4 – 6 mg/kg),  patients with ANT 
had  no serious adverse events during 42 days of 
follow-up. Their safety profi le is similar with their 
comparison group. It could happened that although 
Table 2. Polymerase chain reaction uncorrected and corrected effi cacy of Artemisinin Naphthoquine (ANT ) vs 
Dihydroartemisinin Piperaquine (DHP) during follow-up period in any-malaria
Drug Analysis
                 Effi cacy (Polymerase chain reaction)
Uncorrected p Corrected p
Day 14
ANT
mITT
90.1% (64/71)
0.10
90.1% (64/71)
0.11
DHP 92.8% (90/97) 92.8% (90/97)
ANT
PP
100% (61/61)
1.00
100% (61/61)
1.00
DHP 100% (87/87) 100% (87/87)
Day 28
ANT
mITT
84.5% (60/71)
0.12
84.5 % (60/71)
0.013
DHP 87.6% (85/97) 87.6% (85/97)
ANT
PP
98.4% (60/61)
0.09
98.4% (60/61)
0.09
DHP 97.7% (85/87) 97.7% (85/87)
Day 42
ANT
mITT
78.9% (56/71)
0.94
81.7% (58/71)
0.92
DHP 82.5 % (80/97) 82.5 % (80/97)
ANT
PP
91.8 (56/61)
0.28
95.1% (58/61)
0.39
DHP 91.9% (80/87) 91.9%(80/87)
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the dose was high, it was less than the study dosage 
used in pre-clinical studies.12
This single dose of ANT may benefi t the public health 
by increasing patients compliance. Increase patients 
compliance will resulted in decreasing rate of anti-
malarial resistance.13 A study in Kenya showed that 
a shorter duration of arthemeter-lumefantrine with 
fewer tablets were likely to improve compliance of 
patients to AL.14 
There are some limitations, our design is not a 
randomized control trial, number of samples is less 
than the planed sample size, and some problems 
with sample: 7.1% of samples are negative malaria 
by expert NIHRD microscopist and 12.4% were in-
complete follow up (withdrawal of consent and lost 
to follow up). Consequently, the fi ndings may not 
apply to other populations, and further randomized 
studies are needed to support this fi ndings.
We conclude that the use of a single dose of ANT is 
safe and as effi cacious as  DHP for use at the remote 
Primary Health Care facilities for treatment of adults 
and children with uncomplicated malaria. 
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